Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
39.68
+1.11 (2.88%)
At close: Mar 6, 2026, 4:00 PM EST
39.74
+0.06 (0.15%)
After-hours: Mar 6, 2026, 7:52 PM EST
Soleno Therapeutics Employees
Soleno Therapeutics had 182 employees as of December 31, 2025. The number of employees increased by 90 or 97.83% compared to the previous year.
Employees
182
Change (1Y)
90
Growth (1Y)
97.83%
Revenue / Employee
$1,046,181
Profits / Employee
$112,500
Market Cap
2.05B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| Iovance Biotherapeutics | 975 |
| Ascentage Pharma Group International | 605 |
| Galapagos NV | 558 |
| Syndax Pharmaceuticals | 298 |
| Celldex Therapeutics | 198 |
| Stoke Therapeutics | 128 |
| Mesoblast | 81 |
SLNO News
- 9 days ago - Soleno Therapeutics, Inc. (SLNO) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR - GlobeNewsWire
- 2 months ago - Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT™ XR in the Journal of Clinical Endocrinology and Metabolism - GlobeNewsWire
- 2 months ago - Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses - PRNewsWire
- 3 months ago - Soleno Therapeutics Announces the Passing of Board Member William G. Harris - GlobeNewsWire
- 4 months ago - Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKAT XR Starts, Discontinuations; Shares Down 26% – Hagens Berman - GlobeNewsWire
- 4 months ago - Soleno Therapeutics, Inc. Investigated by the Portnoy Law Firm - GlobeNewsWire
- 4 months ago - Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement - GlobeNewsWire